Vivos Therapeutics Inc (VVOS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Vivos Therapeutics Inc (VVOS) has a cash flow conversion efficiency ratio of 0.790x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.15 Million) by net assets ($-3.99 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Vivos Therapeutics Inc (VVOS) market capitalisation for the company's overall valuation and market capitalisation.
Vivos Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Vivos Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Vivos Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vivos Therapeutics Inc ranked by their cash flow conversion efficiency. See how well can Vivos Therapeutics Inc service its debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Activate Energy Acquisition Corp. Warrant
NASDAQ:AEAQW
|
N/A |
|
Datadot Technology Ltd
AU:DDT
|
-0.008x |
|
Property Franchise Group PLC
LSE:TPFG
|
0.089x |
|
H&T Group plc
LSE:HAT
|
0.033x |
|
Libas Consumer Products Limited
NSE:LIBAS
|
0.001x |
|
Epsium Enterprise Limited Ordinary Shares
NASDAQ:EPSM
|
-0.039x |
|
Planet Properindo Jaya Pt
JK:PLAN
|
-0.004x |
|
Maple Peak Investments Inc
V:MAP
|
-0.062x |
Annual Cash Flow Conversion Efficiency for Vivos Therapeutics Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Vivos Therapeutics Inc from 2018 to 2025. View Vivos Therapeutics Inc share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-1.55 Million | $-15.26 Million | 9.847x | +717.16% |
| 2024-12-31 | $7.95 Million | $-12.69 Million | -1.596x | +94.51% |
| 2023-12-31 | $411.00K | $-11.95 Million | -29.066x | -612.43% |
| 2022-12-31 | $4.80 Million | $-19.59 Million | -4.080x | -562.18% |
| 2021-12-31 | $25.54 Million | $-15.73 Million | -0.616x | -83.50% |
| 2020-12-31 | $16.92 Million | $-5.68 Million | -0.336x | -118.50% |
| 2019-12-31 | $-2.94 Million | $-5.34 Million | 1.815x | +264.83% |
| 2018-12-31 | $4.83 Million | $-5.31 Million | -1.101x | -- |
About Vivos Therapeutics Inc
Vivos Therapeutics, Inc. operates as a medical technology and healthcare services company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnorma… Read more